In:
Cancer, Wiley, Vol. 129, No. 18 ( 2023-09-15), p. 2773-2788
Abstract:
The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)‐status to HER2‐low has made a major impact in the field of oncology. Because there is no consensus regarding the sequencing of the HER2‐targeting agents in HER2‐low breast cancers, the treatment options for HER2‐low breast cancer are enumerated and a treatment‐sequencing algorithm based on the current clinical evidence proposed.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v129.18
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Bookmarklink